Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

enfortumab vedotin 4pembrolizumab 2Gemcitabine 2Cisplatin 2vinflunine 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1avelumab 1adavosertib 1X-Rays 1Trastuzumab 1Surgical Procedures, Operative 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Urinary Bladder Neoplasms × Surgical Procedures, Operative × Clear all
NCT03924895 2025-08-28

KEYNOTE-905

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
595 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡